Evidence map›Paper›PMID 29511780›Full record

Trial reportEuropean journal of clinical pharmacology2018

Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males.

Ganesh V Sangle, Mohan Patil, Nitin J Deshmukh, Sushant A Shengule, Shantibhushan Kamble, Kiran Kumar Vuppalavanchu, Sushil Kale, Mirza Layeeq Ahmed Baig, Geetchandra Singh, Javed Shaikh and 2 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Ganesh V SangleDiabetes Research Lab, New Drug Discovery, Wockhardt Research Centre, Aurangabad, Maharashtra, India. gsangle@wockhardt.com.
Mohan PatilDiabetes Research Lab, New Drug Discovery, Wockhardt Research Centre, Aurangabad, Maharashtra, India.
Nitin J DeshmukhDiabetes Research Lab, New Drug Discovery, Wockhardt Research Centre, Aurangabad, Maharashtra, India.
Sushant A ShenguleDiabetes Research Lab, New Drug Discovery, Wockhardt Research Centre, Aurangabad, Maharashtra, India.
Shantibhushan KambleClinical Pharmacokinetics and Biopharmaceutics Department, Wockhardt Research Centre, Aurangabad, Maharashtra, India.
Kiran Kumar VuppalavanchuClinical Pharmacokinetics and Biopharmaceutics Department, Wockhardt Research Centre, Aurangabad, Maharashtra, India.
Sushil KaleClinical Pharmacokinetics and Biopharmaceutics Department, Wockhardt Research Centre, Aurangabad, Maharashtra, India.
Mirza Layeeq Ahmed BaigClinical Pharmacokinetics and Biopharmaceutics Department, Wockhardt Research Centre, Aurangabad, Maharashtra, India.
Geetchandra SinghClinical Pharmacokinetics and Biopharmaceutics Department, Wockhardt Research Centre, Aurangabad, Maharashtra, India.
Javed ShaikhClinical Pharmacokinetics and Biopharmaceutics Department, Wockhardt Research Centre, Aurangabad, Maharashtra, India.
Jitendra TripathiClinical Pharmacokinetics and Biopharmaceutics Department, Wockhardt Research Centre, Aurangabad, Maharashtra, India.
P AravindababuClinical Pharmacokinetics and Biopharmaceutics Department, Wockhardt Research Centre, Aurangabad, Maharashtra, India.
Wockhardt (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSitagliptin, a dipeptidyl peptidase (DPP)-IV inhibitor approved for the treatment of type 2 diabetes, is reported to be more efficacious in Indian patients than non-Indian patient population. The objective of the study was to evaluate pharmacokinetic and pharmacodynamic (PK/PD) parameters of single-dose sitagliptin 100 mg (Januvia) in healthy Indian male participants.

methodIn a randomised, single-dose, open-label, three-treatment, three-period, three-sequence, crossover bioavailability study, 18 healthy male participants received single-dose of sitagliptin under fasted and fed conditions. PK parameters (C

resultsPK parameters expressed in mean (SD) were C

conclusionAlthough, there are differences in pharmacokinetic parameters, no clinically meaningful differences were observed with respect to DPP-IV inhibition between Indian and non-Indian population.

Indexed as

AdolescentAdultCross-Over StudiesDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsFastingGlucagon-Like Peptide 1Healthy VolunteersHumansInsulinMaleSitagliptin PhosphateWhite PeopleYoung AdultDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDPP4 protein, humanGlucagon-Like Peptide 1InsulinSitagliptin PhosphateDPP-IV inhibitorsIncretinsPharmacodynamicsPharmacokineticsSitagliptin

Identifiers

PMID29511780
OpenAlexW2793957393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.